Lv0
0 积分 2023-01-29 加入
Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell–mediated antitumor immune response
1小时前
待确认
Deficiencies in the CD19 complex
2个月前
已完结
Exploring the next generation of antibody–drug conjugates
2个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
2个月前
已完结
Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies
3个月前
已完结
An Updated Review of Interleukin-2 Therapy in Cancer and Autoimmune Diseases
4个月前
已完结
Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances
4个月前
已完结
Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer
4个月前
已完结
Four‐year review of New Zealand laboratory infliximab and adalimumab concentration results indicating potential for improved dosing
5个月前
已完结
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
7个月前
已完结
皖公网安备34019202002308
